ANDS: I’m with you—i.e. skeptical of the company’s assertion that ANA598 is one of the most attractive drug candidates in the HCV arena. To the contrary, ANA598 strikes me as a drug with a narrow therapeutic window (#msg-47087879), and it appears to be inferior to, among others, VX-222, the non-nuke from VRTX.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.